Romosozumab Biosimilar Monoclonal Antibody (SOST) for Research

Cat No.: GMP-Bios-ab-493

Pre-Made Romosozumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Romosozumab, sold under the brand name Evenity, is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-493-1mg 1mg 243

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Romosozumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody
INN Name Romosozumab
TargetSOST
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesChiroscienceGroup plc;Amgen;UCB
Conditions ApprovedMale osteoporosis;Postmenopausal osteoporosis
Conditions Activena
Conditions DiscontinuedFracture
Development Techna



About target - SOST

1. Protein Sclerostin

2. Gene SOST

3. Organism Homo sapiens (Human)

Function
Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.